|Bid||70.86 x 1000|
|Ask||75.11 x 1000|
|Day's Range||72.93 - 73.24|
|52 Week Range||36.82 - 75.82|
|Beta (5Y Monthly)||1.30|
|PE Ratio (TTM)||55.31|
|Earnings Date||Aug 02, 2021 - Aug 06, 2021|
|Forward Dividend & Yield||0.16 (0.22%)|
|Ex-Dividend Date||May 28, 2021|
|1y Target Est||73.08|
Bruker (BRKR) updates 2021 financial guidance encouraged by solid business growth and high-growth opportunities.
View more earnings on BRKRSee more from BenzingaClick here for options trades from BenzingaCyclo Therapeutics Shares Move Higher On Kickstart Of Late-Stage NPC Trial With Trappsol CycloAmneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
BILLERICA, Mass., Jun 17, 2021--At its 2021 Virtual Investor Day today, Bruker Corporation (Nasdaq: BRKR) will discuss the Company’s strategy and Project Accelerate 2.0 initiatives, including the Company’s potential high-growth opportunities in the areas of proteomics and spatial biology. Bruker will also update its fiscal year 2021 guidance and will discuss its medium term financial outlook through 2024.